Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT06796673

Retina BioBank: Retina Biomarkers for a Deeper Understanding of Vitreoretinal and Systemic Diseases

Status
Enrolling By Invitation
Phase
Study type
Observational
Enrollment
10,000 (estimated)
Sponsor
Greater Houston Retina Research · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The RBBK study is a non-interventional, prospective study that will characterize disease state biomarker levels from aqueous humor, vitreous humor, intraoperative tissue and saliva of subjects with various retinal and systemic pathologies.

Detailed description

The RBBK study is a non-interventional, prospective study that will characterize disease state biomarker levels from aqueous humor, vitreous humor, intraoperative tissue and saliva of subjects with various retinal and systemic pathologies. Participants are eligible to be included in the study only if all of the following criteria apply: 1. Men or women \> 18 years of age 2. Subjects with vitreoretinal disease in at least one eye receiving a retinal treatment intervention 3. Able and willing to provide signed informed consent The study will consist of a single visit and a retrospective chart review. The study visit will consist of: 1. Screening for eligibility; 2. Aqueous humor collection (if applicable); 3. Vitreous humor collection (if applicable); 4. Intraoperative tissue (if applicable); and 5. Saliva collection If applicable, approximately 50 microliters (or more, up to 1000 microliters) of aqueous fluid will be collected by anterior chamber paracentesis according to standard clinical procedures. If applicable, up to 2 milliliters of vitreous fluid will be collected according to standard clinical procedures. Specific tissue, such as scar tissue, are routinely removed from the eye during vitreoretinal procedures. When being removed during a standard of care surgical procedure, these tissues may be collected. Saliva will also be collected according to instructions found in the Saliva Oragene Dx Collection Kit.

Conditions

Timeline

Start date
2022-04-11
Primary completion
2032-04-01
Completion
2032-08-01
First posted
2025-01-28
Last updated
2025-01-28

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT06796673. Inclusion in this directory is not an endorsement.